NASDAQ:ONCE - Spark Therapeutics Stock Price, Price Target & More

$81.13 -0.03 (-0.04 %)
(As of 04/20/2018 02:06 PM ET)
Previous Close$81.16
Today's Range$80.50 - $82.53
52-Week Range$41.06 - $91.75
Volume356,343 shs
Average Volume702,404 shs
Market Capitalization$3.03 billion
P/E Ratio-10.56
Dividend YieldN/A
Beta2.56

About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics logoSpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCE
CUSIPN/A
Phone888-772-7560

Debt

Debt-to-Equity RatioN/A
Current Ratio9.93%
Quick Ratio9.93%

Price-To-Earnings

Trailing P/E Ratio-10.56
Forward P/E Ratio-24.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.07 million
Price / Sales250.18
Cash FlowN/A
Price / CashN/A
Book Value$13.88 per share
Price / Book5.85

Profitability

EPS (Most Recent Fiscal Year)($7.63)
Net Income$-253,480,000.00
Net Margins-2,100.80%
Return on Equity-59.38%
Return on Assets-51.66%

Miscellaneous

Employees315
Outstanding Shares37,220,000

How to Become a New Pot Stock Millionaire

Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics (NASDAQ:ONCE) released its earnings results on Tuesday, February, 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($1.73). The biotechnology company earned $7.41 million during the quarter, compared to the consensus estimate of $9.53 million. Spark Therapeutics had a negative return on equity of 59.38% and a negative net margin of 2,100.80%. View Spark Therapeutics' Earnings History.

What price target have analysts set for ONCE?

20 equities research analysts have issued 1 year price targets for Spark Therapeutics' stock. Their predictions range from $40.00 to $113.00. On average, they anticipate Spark Therapeutics' share price to reach $70.5789 in the next year. View Analyst Ratings for Spark Therapeutics.

What are Wall Street analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:
  • 1. Mizuho analysts commented, "We expect the first Luxturna patients to be treated in 2Q18 in the U.S. while regulatory action is expected by the EMA in 3Q18." (2/21/2018)
  • 2. Cantor Fitzgerald analysts commented, "We believe Spark’s licensing and supply agreement with Novartis (NVS – Not Covered) for LUXTURNA’s ex-U.S. rights further emphasizes the significant value of the approved gene therapy’s commercial opportunity." (1/24/2018)
  • 3. Chardan Capital analysts commented, "We also see it as a important positive on Spark corporate governance that, e.g. during the panel, Spark provided caution to the panel attendees when panelists seemed interested in the potential for Luxturna re-treatment to further improve vision by treating more of the retina. (Spark noted that the company had not yet generated such data and responsibly urged caution.) After the unanimous backing of the panel, Luxturna, which has a PDUFA date of 12 January 2018, could achieve a number of firsts if approved, i.e." (10/13/2017)
  • 4. Cowen Inc analysts commented, "The FDA’s briefing documents appear mostly benign with most discussion centered." (10/10/2017)

Who are some of Spark Therapeutics' key competitors?

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Marrazzo M.B.A., M.P.A., Co-Founder, CEO & Director (Age 39)
  • Dr. Katherine A. High, Co-Founder, Pres and Chief Scientific Officer (Age 66)
  • Mr. Stephen W. Webster, Chief Financial Officer (Age 57)
  • Mr. John Furey, Chief Operating Officer (Age 53)
  • Mr. Daniel R. Faga, Chief Bus. Officer (Age 38)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Has Spark Therapeutics been receiving favorable news coverage?

News stories about ONCE stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spark Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.41 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Spark Therapeutics?

Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of ONCE stock can currently be purchased for approximately $81.13.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $3.03 billion and generates $12.07 million in revenue each year. The biotechnology company earns $-253,480,000.00 in net income (profit) each year or ($7.63) on an earnings per share basis. Spark Therapeutics employs 315 workers across the globe.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]


MarketBeat Community Rating for Spark Therapeutics (ONCE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  588
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spark Therapeutics (NASDAQ:ONCE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Spark Therapeutics in the last 12 months. Their average twelve-month price target is $70.5789, suggesting that the stock has a possible downside of 13.01%. The high price target for ONCE is $113.00 and the low price target for ONCE is $40.00. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.682.83
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $70.5789$70.5789$74.6667$91.6471
Price Target Upside: 13.01% downside9.42% upside44.90% upside8.81% upside

Spark Therapeutics (NASDAQ:ONCE) Consensus Price Target History

Price Target History for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ:ONCE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2018William BlairReiterated RatingBuyLowView Rating Details
3/29/2018MizuhoSet Price TargetBuy$79.00LowView Rating Details
3/8/2018Credit Suisse GroupReiterated RatingOutperform -> Outperform$61.00 -> $75.00MediumView Rating Details
2/21/2018Raymond JamesSet Price TargetBuy$66.00HighView Rating Details
2/21/2018BMO Capital MarketsSet Price TargetOutperform -> Buy$66.00 -> $64.00MediumView Rating Details
2/21/2018Sanford C. BernsteinReiterated RatingBuy$71.00 -> $60.00LowView Rating Details
2/21/2018Stifel NicolausReiterated RatingBuy -> Buy$73.00 -> $64.00LowView Rating Details
2/20/2018Cantor FitzgeraldSet Price TargetBuy$100.00LowView Rating Details
2/14/2018JPMorgan ChaseDowngradeOverweight -> Neutral$62.00 -> $60.00LowView Rating Details
2/8/2018Royal Bank of CanadaReiterated RatingOutperform -> Outperform$65.00HighView Rating Details
1/25/2018WedbushReiterated RatingUnderperform -> Positive$35.00 -> $40.00MediumView Rating Details
1/23/2018BarclaysReiterated RatingOverweight -> Buy$61.00 -> $64.00LowView Rating Details
1/4/2018SunTrust BanksBoost Price TargetBuy$113.00HighView Rating Details
12/14/2017Goldman SachsDowngradeBuy -> Neutral$106.00 -> $58.00LowView Rating Details
12/12/2017Chardan CapitalLower Price TargetBuy -> Buy$100.00 -> $60.00HighView Rating Details
12/12/2017Leerink SwannDowngradeOutperform -> Market Perform$49.00HighView Rating Details
12/12/2017UBSDowngradeBuy -> Neutral$92.00 -> $51.00HighView Rating Details
10/10/2017CowenReiterated RatingBuy$95.00N/AView Rating Details
10/10/2017Jefferies GroupReiterated RatingBuy$95.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$83.00HighView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Spark Therapeutics (NASDAQ:ONCE) Earnings History and Estimates Chart

Earnings by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ:ONCE) Earnings Estimates

2018 EPS Consensus Estimate: ($3.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185($1.71)$1.20($0.99)
Q2 20185($1.76)$1.68($0.87)
Q3 20185($1.12)($0.66)($0.88)
Q4 20185($1.63)($0.06)($1.08)

Spark Therapeutics (NASDAQ ONCE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018Q4 2017($1.73)($1.73)$9.53 million$7.41 millionViewListenView Earnings Details
11/7/2017Q3 2017($1.79)($1.90)$1.40 million$1.90 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.75)($1.89)$1.33 million$1.48 millionViewListenView Earnings Details
5/9/2017Q1 2017($1.36)($1.70)$1.35 million$1.27 millionViewListenView Earnings Details
2/22/2017Q416($1.12)($1.21)$1.32 million$16.30 millionViewListenView Earnings Details
11/3/2016Q316($1.01)($1.07)$1.26 million$1.30 millionViewN/AView Earnings Details
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)$1.30 million$17.20 millionViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Spark Therapeutics (NASDAQ:ONCE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Spark Therapeutics (NASDAQ ONCE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.30%
Insider Trading History for Spark Therapeutics (NASDAQ:ONCE)
Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ ONCE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018John FureyCOOSell13,277$82.52$1,095,618.042,277View SEC Filing  
4/12/2018John FureyCOOSell20,000$77.51$1,550,200.0020,000View SEC Filing  
12/11/2017John FureyCOOSell18$46.33$833.94View SEC Filing  
12/8/2017John FureyCOOBuy18$73.48$1,322.64View SEC Filing  
11/28/2017Katherine A HighInsiderSell5,000$71.32$356,600.00215,000View SEC Filing  
11/16/2017Stephen W WebsterCFOSell10,000$70.14$701,400.0012,500View SEC Filing  
11/13/2017Barge Joseph LaInsiderSell5,500$71.44$392,920.008,146View SEC Filing  
11/13/2017Jeffrey D MarrazzoCEOSell20,000$71.54$1,430,800.00250,000View SEC Filing  
11/9/2017Barge Joseph LaInsiderSell3,309$71.31$235,964.798,146View SEC Filing  
10/31/2017Katherine A HighInsiderSell5,000$83.30$416,500.00215,000View SEC Filing  
10/24/2017Daniel FagaInsiderSell7,500$80.96$607,200.006,000View SEC Filing  
10/20/2017Daniel FagaInsiderSell6,000$79.95$479,700.006,000View SEC Filing  
9/26/2017Katherine A HighInsiderSell5,000$86.16$430,800.00215,000View SEC Filing  
9/21/2017Hospital Of Philade Children'sDirectorSell1,000,000$84.63$84,630,000.003,928,707View SEC Filing  
9/19/2017Daniel FagaInsiderSell1,500$85.00$127,500.001,500View SEC Filing  
9/12/2017Daniel FagaInsiderSell6,000$82.50$495,000.006,000View SEC Filing  
9/7/2017Daniel FagaInsiderSell3,000$85.02$255,060.003,000View SEC Filing  
9/5/2017Barge Joseph LaInsiderSell5,500$81.00$445,500.0010,825View SEC Filing  
8/29/2017Katherine A HighInsiderSell10,000$80.25$802,500.00220,000View SEC Filing  
8/23/2017Jeffrey D MarrazzoCEOSell21,350$80.01$1,708,213.50251,350View SEC Filing  
8/15/2017Stephen W WebsterCFOSell10,000$79.38$793,800.0012,500View SEC Filing  
8/11/2017Jeffrey D MarrazzoCEOSell15,000$75.10$1,126,500.00245,000View SEC Filing  
8/2/2017Jeffrey D MarrazzoCEOSell28,650$80.01$2,292,286.50258,650View SEC Filing  
7/31/2017Stephen W WebsterCFOSell2,337$71.12$166,207.444,837View SEC Filing  
7/25/2017Katherine A HighInsiderSell10,000$72.53$725,300.00220,000View SEC Filing  
7/24/2017Anand MehraDirectorSell211,858$70.15$14,861,838.70View SEC Filing  
7/24/2017Daniel FagaInsiderSell3,000$70.00$210,000.003,000View SEC Filing  
7/5/2017Jeffrey D MarrazzoCEOSell5,669$65.00$368,485.00235,669View SEC Filing  
6/29/2017Daniel FagaInsiderSell4,500$62.71$282,195.004,500View SEC Filing  
6/27/2017Katherine A HighInsiderSell10,000$60.96$609,600.00220,000View SEC Filing  
6/21/2017Anand MehraDirectorSell6,302$65.00$409,630.00View SEC Filing  
6/21/2017Jeffrey D MarrazzoCEOSell9,331$65.00$606,515.00230,534View SEC Filing  
6/19/2017Katherine A HighInsiderSell10,000$60.00$600,000.00220,000View SEC Filing  
6/19/2017Stephen W WebsterCFOSell7,663$60.00$459,780.0010,163View SEC Filing  
6/7/2017Barge Joseph LaGeneral CounselSell5,000$55.00$275,000.009,567View SEC Filing  
4/25/2017Katherine A HighInsiderSell15,000$55.33$829,950.00212,060View SEC Filing  
4/25/2017Stephen W WebsterCFOSell10,000$55.18$551,800.004,398View SEC Filing  
4/24/2017Katherine A HighInsiderSell2,060$55.01$113,320.60212,060View SEC Filing  
4/24/2017Stephen W WebsterCFOSell1,898$55.00$104,390.004,398View SEC Filing  
4/3/2017Barge Joseph LaGeneral CounselSell5,000$52.73$263,650.0010,325View SEC Filing  
3/1/2017Anand MehraDirectorSell84,654$65.02$5,504,203.08View SEC Filing  
3/1/2017Barge Joseph LaGeneral CounselSell5,000$64.41$322,050.0010,325View SEC Filing  
2/28/2017Anand MehraDirectorSell25,274$65.02$1,643,315.48View SEC Filing  
2/27/2017Anand MehraDirectorSell41,910$65.02$2,724,988.20View SEC Filing  
2/16/2017Anand MehraDirectorSell35,347$65.03$2,298,615.41View SEC Filing  
2/7/2017Anand MehraDirectorSell25,334$65.06$1,648,230.04View SEC Filing  
12/16/2016Anand MehraDirectorSell349,656$53.46$18,692,609.76View SEC Filing  
12/15/2016Barge Joseph LaInsiderSell3,000$52.98$158,940.008,325View SEC Filing  
12/13/2016Anand MehraDirectorSell122,532$55.17$6,760,090.44View SEC Filing  
11/14/2016Katherine A HighInsiderSell10,000$60.30$603,000.00210,000View SEC Filing  
10/17/2016Jeffrey D MarrazzoCEOSell5,000$54.66$273,300.00235,000View SEC Filing  
10/3/2016Barge Joseph LaInsiderSell3,000$60.14$180,420.008,325View SEC Filing  
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00240,000View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00220,500View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.005,768,707View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80236,971View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00240,000View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00230,100View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00242,290View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60242,348View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20246,017View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44242,348View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66246,017View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00235,000View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.0019,716View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.008,325View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.006,768,707View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00235,000View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00270,100View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.0012,825View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.0022,500View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00255,000View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.0019,716View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.907,768,707View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.007,900,212View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00280,000View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00290,000View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00300,000View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00300,000View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00230,000View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00305,000View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.005,383View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.002,500View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.005,000View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spark Therapeutics (NASDAQ ONCE) News Headlines

Source:
DateHeadline
Spark Therapeutics ground-breaking gene therapy now being administered at select hospitalsSpark Therapeutics' ground-breaking gene therapy now being administered at select hospitals
www.bizjournals.com - April 20 at 8:33 AM
Spark Therapeutics' ground-breaking gene therapy now being administered at select hospitalsSpark Therapeutics' ground-breaking gene therapy now being administered at select hospitals
finance.yahoo.com - April 20 at 8:33 AM
Insider Selling: Spark Therapeutics (ONCE) COO Sells 13,277 Shares of StockInsider Selling: Spark Therapeutics (ONCE) COO Sells 13,277 Shares of Stock
www.americanbankingnews.com - April 19 at 7:19 PM
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
finance.yahoo.com - April 19 at 5:32 PM
Spark Therapeutics (ONCE) "Buy" Rating Reaffirmed at William BlairSpark Therapeutics' (ONCE) "Buy" Rating Reaffirmed at William Blair
www.americanbankingnews.com - April 19 at 10:00 AM
Spark Therapeutics (ONCE) Lowered to "Sell" at Zacks Investment ResearchSpark Therapeutics (ONCE) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 18 at 8:00 PM
Spark Therapeutics (ONCE) Downgraded to Sell at ValuEngineSpark Therapeutics (ONCE) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM
Exploring Spark Therapeutics’ Product PipelineExploring Spark Therapeutics’ Product Pipeline
finance.yahoo.com - April 18 at 8:53 AM
Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018
finance.yahoo.com - April 18 at 8:53 AM
Exploring Spark Therapeutics’ Cash FlowsExploring Spark Therapeutics’ Cash Flows
finance.yahoo.com - April 18 at 8:53 AM
A Look at the Financial Performance of Spark TherapeuticsA Look at the Financial Performance of Spark Therapeutics
finance.yahoo.com - April 18 at 8:53 AM
William Blair Comments on Spark Therapeutics Q2 2018 Earnings (ONCE)William Blair Comments on Spark Therapeutics' Q2 2018 Earnings (ONCE)
www.americanbankingnews.com - April 18 at 8:10 AM
Q1 2018 EPS Estimates for Spark Therapeutics Lifted by William Blair (ONCE)Q1 2018 EPS Estimates for Spark Therapeutics Lifted by William Blair (ONCE)
www.americanbankingnews.com - April 17 at 6:51 AM
Spark Therapeutics (ONCE) Stock Rating Upgraded by Zacks Investment ResearchSpark Therapeutics (ONCE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 17 at 12:40 AM
Spark Therapeutics (ONCE) Stock Rating Reaffirmed by Jefferies GroupSpark Therapeutics (ONCE) Stock Rating Reaffirmed by Jefferies Group
www.americanbankingnews.com - April 16 at 9:17 PM
Spark Therapeutics (ONCE) COO Sells $1,550,200.00 in StockSpark Therapeutics (ONCE) COO Sells $1,550,200.00 in Stock
www.americanbankingnews.com - April 16 at 7:14 PM
Sanford C. Bernstein Begins Coverage on Spark Therapeutics (ONCE)Sanford C. Bernstein Begins Coverage on Spark Therapeutics (ONCE)
www.americanbankingnews.com - April 15 at 4:30 PM
Spark Therapeutics (ONCE) Receives Average Rating of "Buy" from AnalystsSpark Therapeutics (ONCE) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 15 at 1:40 PM
Geron Corporation: How The Improved Industry Tailwinds Can Help ImetelstatGeron Corporation: How The Improved Industry Tailwinds Can Help Imetelstat
seekingalpha.com - April 15 at 8:36 AM
Spark Therapeutics (ONCE) Expected to Announce Quarterly Sales of $53.75 MillionSpark Therapeutics (ONCE) Expected to Announce Quarterly Sales of $53.75 Million
www.americanbankingnews.com - April 15 at 6:59 AM
How The Improved Industry Tailwinds Can Help Imetelstat?How The Improved Industry Tailwinds Can Help Imetelstat?
seekingalpha.com - April 14 at 5:36 PM
Netflix Could Be Hero for Weary Tech Investors Needing SparkNetflix Could Be Hero for Weary Tech Investors Needing Spark
www.msn.com - April 14 at 8:38 AM
Spark Therapeutics (ONCE) Rating Reiterated by BMO Capital MarketsSpark Therapeutics (ONCE) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - April 13 at 6:39 PM
Netflix Could Be Hero for Weary Tech Investors Looking for SparkNetflix Could Be Hero for Weary Tech Investors Looking for Spark
www.bloomberg.com - April 13 at 8:43 AM
Traders Buy Large Volume of Spark Therapeutics Put Options (ONCE)Traders Buy Large Volume of Spark Therapeutics Put Options (ONCE)
www.americanbankingnews.com - April 13 at 6:11 AM
Zacks: Brokerages Anticipate Spark Therapeutics (ONCE) to Announce -$0.45 EPSZacks: Brokerages Anticipate Spark Therapeutics (ONCE) to Announce -$0.45 EPS
www.americanbankingnews.com - April 13 at 1:23 AM
Spark Therapeutics Reaches Analyst Target PriceSpark Therapeutics Reaches Analyst Target Price
www.nasdaq.com - April 12 at 9:05 AM
Adaptimmune Announces Changes to Board of DirectorsAdaptimmune Announces Changes to Board of Directors
globenewswire.com - April 12 at 9:05 AM
Sangamo Therapeutics: Deciphering Valuation In The Face Of Key De-Risking EventsSangamo Therapeutics: Deciphering Valuation In The Face Of Key De-Risking Events
seekingalpha.com - April 11 at 5:13 PM
Spark Therapeutics (ONCE) Upgraded to "Buy" at ValuEngineSpark Therapeutics (ONCE) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 10 at 12:33 AM
Spark Therapeutics (ONCE) Earns "Buy" Rating from Cantor FitzgeraldSpark Therapeutics (ONCE) Earns "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - April 7 at 4:29 PM
SunTrust Banks Reiterates "$101.00" Price Target for Spark Therapeutics (ONCE)SunTrust Banks Reiterates "$101.00" Price Target for Spark Therapeutics (ONCE)
www.americanbankingnews.com - April 7 at 12:30 PM
Spark Therapeutics (ONCE) PT Lowered to $98.00Spark Therapeutics (ONCE) PT Lowered to $98.00
www.americanbankingnews.com - April 1 at 11:24 AM
Spark Therapeutics (ONCE) Given a $67.00 Price Target at BMO Capital MarketsSpark Therapeutics (ONCE) Given a $67.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - March 31 at 12:46 AM
Spark Therapeutics (ONCE) Given a $105.00 Price Target at Cantor FitzgeraldSpark Therapeutics (ONCE) Given a $105.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 30 at 10:02 PM
Spark Therapeutics (ONCE) Given a $79.00 Price Target at MizuhoSpark Therapeutics (ONCE) Given a $79.00 Price Target at Mizuho
www.americanbankingnews.com - March 29 at 6:22 PM
$53.75 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter$53.75 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter
www.americanbankingnews.com - March 29 at 8:25 AM
Spark Therapeutics (ONCE) Rating Increased to Hold at ValuEngineSpark Therapeutics (ONCE) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 28 at 10:23 PM
Spark Therapeutics (ONCE) Rating Lowered to Underperform at WedbushSpark Therapeutics (ONCE) Rating Lowered to Underperform at Wedbush
www.americanbankingnews.com - March 28 at 3:12 PM
Spark Therapeutics Inc (ONCE) Receives Average Rating of "Buy" from BrokeragesSpark Therapeutics Inc (ONCE) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 21 at 1:41 PM
Mass. Eye and Ear makes history, injecting $850,000 gene therapy for first timeMass. Eye and Ear makes history, injecting $850,000 gene therapy for first time
finance.yahoo.com - March 20 at 5:25 PM
SXSW on the Future of HealthcareSXSW on the Future of Healthcare
finance.yahoo.com - March 15 at 5:20 PM
Spark Therapeutics Inc (ONCE) Expected to Post Quarterly Sales of $53.75 MillionSpark Therapeutics Inc (ONCE) Expected to Post Quarterly Sales of $53.75 Million
www.americanbankingnews.com - March 11 at 2:14 AM
Zacks: Brokerages Anticipate Spark Therapeutics Inc (ONCE) Will Post Earnings of -$0.45 Per ShareZacks: Brokerages Anticipate Spark Therapeutics Inc (ONCE) Will Post Earnings of -$0.45 Per Share
www.americanbankingnews.com - March 9 at 9:32 PM
Credit Suisse Group Reaffirms Outperform Rating for Spark Therapeutics (ONCE)Credit Suisse Group Reaffirms Outperform Rating for Spark Therapeutics (ONCE)
www.americanbankingnews.com - March 8 at 8:40 AM
Sectoral Asset Management Inc Sells 33,209 Shares of Spark Therapeutics Inc (ONCE)Sectoral Asset Management Inc Sells 33,209 Shares of Spark Therapeutics Inc (ONCE)
www.americanbankingnews.com - March 5 at 3:34 PM
Spark Therapeutics Inc (ONCE) Shares Bought by State of Wisconsin Investment BoardSpark Therapeutics Inc (ONCE) Shares Bought by State of Wisconsin Investment Board
www.americanbankingnews.com - March 5 at 1:56 PM
Landscape Capital Management L.L.C. Takes Position in Spark Therapeutics Inc (ONCE)Landscape Capital Management L.L.C. Takes Position in Spark Therapeutics Inc (ONCE)
www.americanbankingnews.com - March 5 at 11:31 AM
Spark Therapeutics (ONCE) Rating Increased to Sell at ValuEngineSpark Therapeutics (ONCE) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 4 at 12:48 PM
William Blair Brokers Lift Earnings Estimates for Spark Therapeutics Inc (ONCE)William Blair Brokers Lift Earnings Estimates for Spark Therapeutics Inc (ONCE)
www.americanbankingnews.com - March 2 at 10:24 AM

SEC Filings

Spark Therapeutics (NASDAQ:ONCE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Spark Therapeutics (NASDAQ:ONCE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Spark Therapeutics (NASDAQ ONCE) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.